

Crazy Zzzcat
 Female, 22 year old, 1/1/2000
 MRN: 2050013133
 Phone: 252-123-4567
 Preferred Language: Spanish
 Code: Not on file (no ACP docs)

TEST PATIENT

Search

COVID-19 Vaccine: Overdue for dose 2

COVID-19: Positive 1/18/2022

No PCP

Coverage: None

Allergies (4)

No patient types

1/18 TELEMEDICINE VISIT

BMI: 14.14 kg/m² !

SINCE LAST WILSON COMMUNITY HEALTH CENTER VISIT

No visits

Lab (1) *

CARE GAPS

Lipid Screening

Hepatitis C Screening

Cervical Cancer Screening (P...

10 more care gaps

+1 awaiting completion

PROBLEM LIST

Schizoaffective disorder,

1/18/2022 visit with Holly Gentry for Telemedicine Visit

ROOMING Connect Episodes Programs Chief Complaint UDS Vitals Pt Rpt Vitals PISQ+SINC Review Allergies Me
 SOGI Screenings Pt Questionnaires Meds & Orders Hearing/Vision Patient Touches Imm Risk Care Teams SmartSets

MyChart Signup

Guidance

For treatment of patients who are high risk for progression to severe COVID:		Start within 5 days of symptom onset	Start within 10 days of symptom onset	Start within 7 days of symptom onset	Start within 5 days of symptom onset
		Paxlovid (Pfizer)	Sotrovimab	Remdesivir	Lagevrio (Merck)
Age & Weight	< 12 years, any weight	No	No	No	No
	12-17 years, < 40 kg	No	No	No	No
	12-17 years, 40+ kg	Yes	Yes	Yes	No
	18+ years, < 40 kg	No	No	No	Yes
	18+ years, 40+ kg	Yes	Yes	Yes	Yes
Renal	eGFR > 60	Yes	Yes	Yes	Yes
	eGFR 30-60	Dose reduce	Yes	Yes	Yes
	eGFR < 30	No	Yes	No	Yes
Hepatic	Child-Pugh Class A or B	Yes	Yes	Unclear	Yes
	Child-Pugh Class C	No	Yes	Unclear	Yes
Reproduction*	Currently pregnant	Yes	Yes	Yes	No
	Currently lactating	Yes	Yes	Yes	Must pump & dump during treatment and for 4 days after
	Currently using combined hormonal contraceptives	Use additional barrier method	Yes	Use additional barrier method	Yes
	Individuals with pregnancy potential	Yes	Yes	Yes	Pregnancy test prior to treatment; use effective contraception for 4 days after
	Men with reproductive potential	Yes	Yes	Yes	Use contraception during treatment and for 3 months after
Medications	Strong inducers of P-glycoprotein	Yes	Yes	Unclear	Yes
	Hydroxychloroquine or chloroquine	Yes	Yes	No	Yes
	Drugs highly dependent on CYP3A for clearance or are potent CYP3A inducers	No	Yes	Yes	Yes
Prescribing information		Paxlovid	Sotrovimab	Remdesivir (NEJM)	Molnupiravir

* See Society for Maternal Fetal Medicine guidance.

Remdesivir (hospitalized patients): https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf